Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With the upcoming 2026 revision of ISO 10993-1 expected to introduce significant updates to the biological evaluation of medical devices, how can manufacturers effectively vet and select a contract re...
As the UK's regulatory framework for medical devices continues to evolve, what are the core legal obligations and strategic considerations for non-UK manufacturers appointing a UK Responsible Person (...
As the UK's regulatory framework for medical devices continues to evolve post-Brexit, what are the key strategic considerations for non-UK manufacturers regarding the role and responsibilities of thei...
Given the evolving EU regulatory landscape, what comprehensive framework should a non-EU manufacturer use to select a qualified EU Responsible Person (RP) for cosmetic products, ensuring the chosen pa...
When considering the cost of appointing an EU Responsible Person (RP) to meet upcoming compliance deadlines, what are the key service components and portfolio characteristics that typically influence ...
For non-EU medical device manufacturers aiming to enter the European market, appointing an EU Authorised Representative (AR) is a mandatory requirement under the Medical Device Regulation (EU) 2017/74...
For sponsors of connected medical devices, such as a Class II SaMD or a device with wireless capabilities, how can a premarket submission's cybersecurity section be structured to provide a comprehensi...
With the EU Medical Device Regulation (MDR) fundamentally reshaping the role of the EU Authorized Representative (AR), and with new guidance from the Medical Device Coordination Group (MDCG) continuin...
For non-EU manufacturers placing medical devices on the European market, appointing an EU Authorized Representative (AR) is a mandatory requirement under the EU Medical Device Regulation (MDR). While ...
With the United Kingdom's medical device regulatory framework undergoing significant evolution, how should non-UK manufacturers strategically evaluate the role and responsibilities of their UK Respons...
With the heightened responsibilities and legal liability assigned to the EU Authorized Representative (AR) under the Medical Device Regulation (MDR), how should a non-EU medical device manufacturer st...
When preparing a premarket submission for a connected medical device, how should manufacturers structure their cybersecurity documentation to align with FDA expectations? Beyond simply listing securit...
For manufacturers of moderate-risk, Class II in vitro diagnostic (IVD) devices, such as a pharmacogenetic assessment system or instrumentation for a clinical multiplex test system, what is the role of...
When budgeting for compliance into 2026 and beyond, how should an organization analyze the potential costs of engaging a GDPR Article 27 Representative? While specific fees vary, understanding the und...
When non-EU medical device manufacturers plan to enter the European market, they must appoint an EU Authorized Representative (AR) as mandated by the Medical Device Regulation (MDR). This AR serves as...
As non-EU importers prepare for the definitive phase of the Carbon Border Adjustment Mechanism (CBAM), a primary concern is understanding the financial implications of appointing a representative for ...
While it is not possible to state a specific dollar amount for FDA U.S. Agent services for 2026, as these are provided by private entities with market-driven fees, foreign medical device establishment...
As the Modernization of Cosmetics Regulation Act (MoCRA) establishes new requirements for foreign cosmetic facilities, many are asking about the cost of appointing a mandatory FDA U.S. Agent. While sp...
GDPR is not a scam. Scammers exploit it
For non-EU manufacturers of medical devices, selecting an EU Authorised Representative (AR) is a critical step for market access under the EU MDR. Beyond simply providing a European address, what are ...